國立高雄大學圖資館 |

Language: English

Back

A roadmap for curing cancer, Alzheim...

Marangos, Paul J.,

A roadmap for curing cancer, Alzheimer's, and cardiovascular disease /

Record Type:	Electronic resources : Monograph/item
Title/Author:	A roadmap for curing cancer, Alzheimer's, and cardiovascular disease /Paul J. Marangos.
Author:	Marangos, Paul J.,
Description:	1 online resource
Subject:	CancerTreatment.
Online resource:	https://www.sciencedirect.com/science/book/9780128127964
ISBN:	9780128127971$q(electronic bk.)

A roadmap for curing cancer, Alzheimer's, and cardiovascular disease /
Marangos, Paul J.,

A roadmap for curing cancer, Alzheimer's, and cardiovascular disease /Paul J. Marangos. - 1 online resource

Includes bibliographical references and index.

Front Cover; A Roadmap for Curing Cancer, Alzheimer's, and Cardiovascular Disease; A Roadmap for CuringCancer, Alzheimer's,and CardiovascularDisease; Copyright; Dedication ; Contents; Preface; Acknowledgments; A -- The Reasons for Failure; 1 -- The Medical R&D Fiasco; THE MOST SERIOUS HUMANITARIAN CRISIS; THE MAGNITUDE OF THE PROBLEM; MY JOURNEY THROUGH THE QUAGMIRE; WHERE TO BEGIN; CANCER: FIFTY YEARS OF THE SAME TOXIC DRUGS; NEURODEGENERATIVE DISEASE: CRIMINAL NEGLIGENCE; CARDIOVASCULAR DISEASE: TREATING THE SYMPTOMS; TIME TO GET SERIOUS; REFERENCES.

Cancer, dementia, and cardiovascular disease are responsible for almost two million deaths each year in the United States alone and represent the largest immediate threat to humanity. Over the last century, we have made spectacular advances that have transformed our society - splitting the atom, space travel, telecommunications, and the Internet - but with medical research focused mostly on science for the sake of science, it has yielded precious few cures. A Roadmap for Curing Cancer, Alzheimer's, and Cardiovascular Disease represents a "first of its kind" effort to address both the reasons for this and to posit solutions to fix our broken system, in an effort to finally end this cure crisis. Dr. Marangos draws on 45 years of experience in every aspect of the biomedical R&D field, from basic drug discovery research at the NIH to the co-founding of five drug companies. He has published 252 research papers and edited four books on drug discovery, is co-inventor on 14 patents, and founded "The Journal of Molecular Neuroscience". He argues that from a development perspective, the regulatory, patent, and legal hurdles that force industry to pursue so-called "me-too" drugs rather than cures for terminal diseases must be re-thought. Leadership accountability, strategy, focus, and urgency need to be re-evaluated, and major reforms to the NIH, FDA, and patent codes are proposed.to remedy these impediments to cures. Written for anyone frustrated with the seemingly endless threat of terminal disease, this book seeks to inform, energize, and provide the rationale for the public and industry stakeholders, as well as clinicians and researchers, to resurrect the physician-patient relationship and demand that we get serious about ridding society of this scourge on humanity. This work contains the views and opinions of the author and are in no way intended to harm the reputation of any person, agency, organization, or commercial entity discussed herein.

ISBN: 9780128127971$q(electronic bk.)Subjects--Topical Terms:

252269
Cancer
--Treatment.Index Terms--Genre/Form:

214472
Electronic books.

LC Class. No.: R850

Dewey Class. No.: 616.831

National Library of Medicine Call No.: W 20.5

A roadmap for curing cancer, Alzheimer's, and cardiovascular disease /
LDR:06191cmm a2200361 i 4500 001 561777
006 m o d
007 cr cnu|||unuuu
008 200213t20172017ne ob 001 0 eng d
020 $a 9780128127971$q(electronic bk.)
020 $a 012812797X$q(electronic bk.)
020 $a 9780128127964
035 $a (OCoLC)985363710 $z (OCoLC)985237408 $z (OCoLC)985389042 $z (OCoLC)985649909 $z (OCoLC)985877942 $z (OCoLC)986100261 $z (OCoLC)986478360 $z (OCoLC)986581113 $z (OCoLC)986917034 $z (OCoLC)988855512 $z (OCoLC)990565815 $z (OCoLC)991540504
035 $a els69900514
040 $a N $b eng $e rda $e pn $c N $d IDEBK $d EBLCP $d YDX $d N $d OCLCF $d OPELS $d UAB $d OCLCO $d MERER $d OCLCQ $d OTZ $d COO $d D6H $d DKU
041 0 $a eng
050 4 $a R850
060 4 $a W 20.5
082 0 4 $a 616.831 $2 23
100 1 $a Marangos, Paul J., $e author. $3 846347
245 1 2 $a A roadmap for curing cancer, Alzheimer's, and cardiovascular disease / $c Paul J. Marangos.
264 1 $a Amsterdam : $b Elsevier, $c [2017]
264 4 $c ©2017
300 $a 1 online resource
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
504 $a Includes bibliographical references and index.
505 0 $a Front Cover; A Roadmap for Curing Cancer, Alzheimer's, and Cardiovascular Disease; A Roadmap for CuringCancer, Alzheimer's,and CardiovascularDisease; Copyright; Dedication ; Contents; Preface; Acknowledgments; A -- The Reasons for Failure; 1 -- The Medical R&D Fiasco; THE MOST SERIOUS HUMANITARIAN CRISIS; THE MAGNITUDE OF THE PROBLEM; MY JOURNEY THROUGH THE QUAGMIRE; WHERE TO BEGIN; CANCER: FIFTY YEARS OF THE SAME TOXIC DRUGS; NEURODEGENERATIVE DISEASE: CRIMINAL NEGLIGENCE; CARDIOVASCULAR DISEASE: TREATING THE SYMPTOMS; TIME TO GET SERIOUS; REFERENCES.
505 8 $a 2 -- Academia Is Marching to the Wrong DrummerSCIENCE FOR ITS OWN SAKE; CHAOTIC POOR-QUALITY SCIENCE; UNIVERSITIES: WHERE IS THE ACCOUNTABILITY?; TECHNOLOGY TRANSFER, WHY BOTHER?; THE COLLABORATION MYTH; THOUGHT LEADERS: BLESSING OR CURSE?; THE NATIONAL INSTITUTES OF HEALTH: WHERE IS THE BEEF?; STRATEGY, ACCOUNTABILITY, AND URGENCY: THE MISSING LINKS; REFERENCES; 3 -- Mavericks Versus the Establishment; MEDICAL RESEARCH 101; ESTABLISHED SCIENCE IS BEING WASTED; MAVERICK SCIENCE, OUR BEST HOPE?; OLD DRUGS FOR NEW USES AND MAVERICKS; GETTING PHYSICIANS BACK IN THE GAME.
505 8 $a NATURAL AGENTS ARE BEING OVERLOOKEDCHARITIES: AN INSULT TO THE CURE QUEST; THE BOTTOM LINE ON THE RESEARCH ENTERPRISE; REFERENCES; 4 -- The Strangled Unincentivized Drug Industry; BIOTECHNOLOGY VERSUS PHARMACEUTICALS, MACRO VERSUS MICRO; BIOLOGICS: GREAT TARGETS BUT TERRIBLE DRUGS; BIOLOGICALS: SUPER EXPENSE FOR MARGINAL BENEFIT; GENE THERAPY AND STEM CELL THERAPY: HYPE VERSUS SUBSTANCE?; THE BIOTECHNOLOGY REPORT CARD; START-UP COMPANIES AND WHY THEY FAIL; VENTURE CAPITAL: SELLING SCIENCE FOR PROFIT; PHARMACEUTICALS: WHERE IS THE BEEF?; CORPORATE PARTNERING, OIL, AND WATER; REFERENCES.
505 8 $a 5 -- The FDA Roadblock to CuresEVOLUTION OF A MONSTER; THE ROCKY ROAD TO DRUG APPROVAL; CLINICAL TRIALS: A VERY INEXACT SCIENCE; PHASE III: THE MOTHER OF ALL CLINICAL TRIALS; MUST WE BE SO TIMID FOR ALL DRUGS?; TERMINAL DISEASE PATIENTS CONDEMNED TO DEATH; THE MISTAKE THAT CREATED THE MONSTER; SURGERY, AN EXAMPLE OF WHAT FEWER REGULATIONS CAN PRODUCE; REGULATION AND THE PATIENT-PHYSICIAN RELATIONSHIP; REFERENCES; 6 -- The Liability Barrier; EVERYONE RESPONDS TO DRUGS DIFFERENTLY; WHERE DOES LIABILITY BEGIN?; MEDICAL CLASS ACTION LAWSUITS: A LITIGATOR'S DREAM; SHOULD WE TRUST THE DRUG COMPANIES?
505 8 $a MALPRACTICE MADNESS WHO WINS?; THE RISK-BENEFIT CONUNDRUM; LIABILITY FOR FAILED CLINICAL TRIALS; REFERENCES; B -- Towards Solutions; 7 -- Cleaning Up the Academic Research Quagmire; REBUILDING THE NATIONAL INSTITUTES OF HEALTH: NASA FOR CURES; WHAT TO DO WITH ACADEMIA AND INDIRECT COSTS?; CHARITIES: YOU HAVE TO BE KIDDING!; QUALITY CONTROL IN RESEARCH; INJECTING STRATEGY AND MANAGEMENT INTO MEDICAL RESEARCH; FEWER THOUGHT LEADERS AND MORE MAVERICKS; THE PUBLIC RIP OFF; REFERENCES; 8 -- Reforming the FDA; THE EVOLUTION OF DRUG REGULATION; RETHINKING THE FDA; SOME COMMON FDA HORROR STORIES.
520 $a Cancer, dementia, and cardiovascular disease are responsible for almost two million deaths each year in the United States alone and represent the largest immediate threat to humanity. Over the last century, we have made spectacular advances that have transformed our society - splitting the atom, space travel, telecommunications, and the Internet - but with medical research focused mostly on science for the sake of science, it has yielded precious few cures. A Roadmap for Curing Cancer, Alzheimer's, and Cardiovascular Disease represents a "first of its kind" effort to address both the reasons for this and to posit solutions to fix our broken system, in an effort to finally end this cure crisis. Dr. Marangos draws on 45 years of experience in every aspect of the biomedical R&D field, from basic drug discovery research at the NIH to the co-founding of five drug companies. He has published 252 research papers and edited four books on drug discovery, is co-inventor on 14 patents, and founded "The Journal of Molecular Neuroscience". He argues that from a development perspective, the regulatory, patent, and legal hurdles that force industry to pursue so-called "me-too" drugs rather than cures for terminal diseases must be re-thought. Leadership accountability, strategy, focus, and urgency need to be re-evaluated, and major reforms to the NIH, FDA, and patent codes are proposed.to remedy these impediments to cures. Written for anyone frustrated with the seemingly endless threat of terminal disease, this book seeks to inform, energize, and provide the rationale for the public and industry stakeholders, as well as clinicians and researchers, to resurrect the physician-patient relationship and demand that we get serious about ridding society of this scourge on humanity. This work contains the views and opinions of the author and are in no way intended to harm the reputation of any person, agency, organization, or commercial entity discussed herein.
650 0 $a Cancer $x Treatment. $3 252269
650 0 $a Alzheimer's disease $x Treatment. $3 188756
650 0 $a Cardiovascular system $x Diseases $x Treatment. $3 280433
650 2 $a Biomedical Research. $3 243625
655 4 $a Electronic books. $2 local. $3 214472
856 4 0 $u https://www.sciencedirect.com/science/book/9780128127964